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Hyperthyroidism is the state of excessive synthesis and release of the thyroid  
hormones by thyrocytes. Graves’ disease is the most common cause of hyperthyroid-
ism in children. The condition may occur at any age but the prevalence increases with 
age. According to the classical paradigm, coexistence of genetic susceptibility, envi-
ronment triggers and immunological dysfunction are responsible for its development. 
Diagnosis of Graves’ disease is based on presence of characteristic clinical symptoms, 
TSH receptor antibodies and excess of thyroid hormones. The management in 
pediatric population involves mainly pharmacotherapy (thyrostatics, β-adrenolitics), 
in resistant cases radical radioiodine I131 therapy or surgical treatment is necessary.
Keywords: hyperthyroidism, Graves’ disease, children, autoantibodies,  
antithyroid drugs
1. Introduction
Hyperthyroidism (hyperthyreosis) is the condition that occurs due to exces-
sive synthesis and release of the thyroid hormones T3 (triiodothyronine) and/or 
T4 (thyroxine) by thyrocytes and as a result of hyperstimulation of cells having 
receptors specific to these hormones.
A negative feedback blocks the secretion of thyrotropin (TSH) from the pitu-
itary gland. Subclinical hyperthyroidism is characterized by normal levels of free 
thyroxine (f T4) and free triiodothyronine (f T3), with TSH below the reference 
range in the blood.
The term “thyrotoxicosis” refers to the clinical syndrome associated with the 
increased level of thyroid hormones caused by their enhanced production by the 
thyroid gland, their excessive release resulting from the gland destruction (e.g. 
the Hashitoxicosis phase in chronic thyroidits of Hashimoto’s type), as well as due 
to the exogenous supply of thyroid hormone preparations in an abnormal, too 
large dose, and casual poisoning with thyroid hormone preparations (thyrotoxi-
cosis factitia). Thus, thyreotoxicosis refers not only to the level of hormones in the 
blood, but is also associated with the level of sensitive cells that undergo activa-
tion, which leads to the manifestation of subjective and objective symptoms.
2. Causes of hyperthyroidism in children
The causes of hyperthyroidism in children include:
• Graves’ disease (toxic diffuse goiter, struma diffusa toxica) accounting for 
95–99% of hyperthyroidism cases in children and approximately 60% in adults.
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• toxic nodular goiter (Plummer’s disease) being much less common in children 
than in adults; most frequently occurring as a single nodule, especially in older 
children.
• the Marine-Lenhart’s syndrome, in which an overactive thyroid nodule  
co-occurs with Graves’ disease in the same patient.
• thyroiditis.
• the initial stage of Hashimoto’s disease.
• phase 1 subacute (viral) thyroiditis.
• poisoning with thyroid hormones – iatrogenic hyperthyroidism.
• Iodine Basedow Syndrome – hyperthyroidism develops due to the application 
of inorganic iodides, which act as triggering factors that induce hyperthyroid-
ism on the grounds of autoimmunization.
• amiodarone-induced thyrotoxicosis (amiodarone has a chemical structure 
resembling that of thyroxine, one tablet contains approximately 75 mg of 
iodine!)
• hyperthyroidism in the course of follicular and papillary cancers.
• McCune-Albright syndrome is associated with the point mutation of the gene 
encoding the alpha subunit of the Gs protein, resulting in permanent activa-
tion of adenylyl cyclase; its main components are: fibrous dysplasia, café au lait 
spots, overactivity of many endocrine glands.
• the so called early effect of radioiodine I131 treatment for the thyroid.
• ovarian goiter (struma ovarii) - a substantial amount of thyroid tissue in 
ovarian tumour.
• thyrotropic pituitary adenomas – secondary hyperthyroidism (elevated values 
of TSH and thyroid hormones).
• pituitary thyroid hormone resistance – elevated levels of TSH and thyroid 
hormones.
• false hyperthyreosis in patients taking biotin preparations – in some cases even 
TSH receptor antibodies appear [1, 2].
3. Etiology and etiopathogenesis of Graves’ disease
The disease is named after an Irish physician, Robert Graves, who was the first 
to describe the symptoms of hyperthyrosis. In non-English speaking countries, the 
two-word term is commonly used as the name of a German doctor, Karl Adolph von 
Basedow, is added. This is an autoimmune disease, in which stimulating antibod-
ies activate TSH receptor, leading to the thyroid growth as well as to unrestrained 




Last decades have shown a constant increase in the incidence of autoimmune 
thyroid diseases (AITD). It is estimated that the problem affects approximately 5% 
of the world population. However, Graves’ disease is rarely diagnosed in the pediat-
ric population. Its prevalence accounts for about 0.02% and children constitute less 
than 5% of all the patients. Nevertheless, it is Graves’s disease that remains the most 
common cause of hyperthyreosis in children, being responsible for 10–15% of all 
thyroid disorders in this group. Among pediatric patients, Graves’ disease may occur 
at any age but the morbidity rate increases with age, having its peak in adolescence. 
Its annual incidence among younger patients is 0.1 per 100,000 as compared to 3.0 
per 100,000 at puberty. In the USA, Graves’ disease affects 0.2–0.4% of children and 
adolescents, i.e. 1 per 10,000, whereas in Hongkong it is diagnosed in 14 children per 
100,000 a year. Sex distribution in the age group of up to 11 years is comparable, but 
in the older age group, girls are more frequently affected than boys (6–8,1).
It is estimated based on the research into monozygotic twins that the etiology of 
AITD has genetic causes in approximately 80% of cases, as compared to 20% due 
to environmental factors. Hashimoto thyroiditis and Graves’ disease share some of 
the genes.
Genes likely to be responsible for the development of AITD can be divided into 
two groups:
1. genes modulating the immune system, i.e. HLA-DR, CD40, CTLA-4, PTPN22, 
CD25, FoxP3.
2. genes specific to the thryroid gland: the gene for thyroglobulin (Tg) and the 
TSH receptor (TSHR) gene.
Additional genes may also play a role, being involved in the differentiation of 
AITD phenotypes, disease severity and response to the therapy.
Genes whose mutations may be responsible for the disease onset include:
• GD-1 (chromosome 14q31).
• GD-2 (chromosome 20q11.2).
• GD-3 (chromosome Xq21).
• HLA-DR3 gene described mainly as the main gene in the development of 
Graves’ disease. The presence of arginine at position 74 of the HLA-DRβ chain 
predisposes to AITD disclosure, whereas glutamine at the same position shows 
protective functions.
• CD40 performs a key function in the interaction between antigen-presenting 
cells and T lymphocytes. CD40, found on B cells, ensures normal signal for 
proliferation, differentiation and production of IgG. Therefore, the CD40 gene 
predisposes to the development of Graves’ disease, which is to a large extent 
B-cell dependent.
• CTLA-4 is present on the surface of T cells and inhibits their excessive 
response to the antigen. Moreover, it shows the expression on regulatory T 
cells, thus playing a major role in promoting their suppresive functions.
• CD25 gene polymorphism inhibits Treg functions, thus promoting autoim-
munity. A latest study has described the level of mRNA expression for the 
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genes encoding T-bet and GATA3, main regulators of Th1 and Th2 differentia-
tion, respectively, and for the cytokines secreted by (IFNγ) and Th2 (IL4) in 
patients with Graves’ disease. The levels of the expression of mRNA T-bet and 
IFNγ are substantially elevated in patients, whereas those of GATA3 and IL4 
remain decreased.
Also mutations of the gene encoding the expression of thyroglobulin, located 
on chromosome 8 and the autoimmune regulator gene located on chromosome 21 
predispose to Graves’ disease. Moreover, vulnerability to develop ophthalmopathy 
in the course of Graves’ disease has been studied, with the involvement of CTLA-4 
genes, tumor necrosis factor α (TNFα), adhesion molecule 1 (ICAM-1), interferon γ 
(IFN-γ), insulin-like growth factor 1 receptor (IGF-1R), protein inhibiting the path-
way of signal 3 transduction (SOCS3), thyroid peroxidase (TPO) and calsequestrin 
1 (CASQ1) [3–5].
The environmental factors that trigger the cascade leading to AITD include:
• infections, both viral and bacterial, may be responsible for the loss of tolerance 
and development of AITD; in the etiology of Graves’ disease Yersinia enteroco-
litica is the best known pathogen having specific bindings to TSH, recognized 
by antibodies against TSH receptor; Y. enterocolitica ompF (outer membrane 
porin F) produces antibodies and according to some sources is responsible for 
the process of molecular mimicry;
• stress -stress hormones (glycocorticosteroids, catecholamines) may induce the 
production of IL4, IL6, IL12 by dendritic cells, stimulate Th2, Th17 or Th1 cells 
and lead to Treg cell apoptosis, which promotes the pathogenesis of Graves’ 
disease;
• radiation -radioiodine treatment for toxic nodular goiter may contribute to the 
development of Graves’ disease or ophthalmopathy; the effect of radiotherapy 
on thyroid function depends on a number of factors, such as age, sex, the 
presence of antithyroid antibodies, iodine intake, etc.;
• exposure to tobacco smoke -according to the available data the proportion of 
smokers is elevated in patients with orbitopathy (64.2%) and Graves’ disease 
(47.9%) as compared to the control group (30%); smoking increases the risk of 
Graves’ disease twice and orbitopathy 3–4 times; moreover, the risk is associ-
ated with treatment failure and severity of ophthalmopathy;
• excessive iodine supply -iodine-induced hyperthyrosis, also called iodine-
Basedow syndrome, refers particularly to patients with nodular goiter or to a 
population in which salt iodination program has been recently implemented;
• medications -interferon-α, alemtuzumab, highly active antiretroviral drugs 
capable of AITD induction; a classic example of the hyperthyreosis-inducing 
drug is amiodarone, a benzuforan derivative rich in iodine, whose structure 
resembles that of thyroid hormones; there are two types of amiodarone-
induced thyrotoxicosis (AIT):
 ○ I -caused by enhanced production of thyroid hormones,




• vitamin D3 deficiency.
• contaminations [6–9].
However, Graves’ disease can be associated with the involvement of a combi-
nation of factors. The disease may even appear a long time after contact with a 
stimulus. Immunologically, the pathogenesis of Hashimoto thyroiditis is based on 
the predominance of cellular response, whereas the pathogenesis of Graves’ disease 
is associated with humoral response. This is, however, a gross simplification, as 
these processes overlap. Up to now, it has been thought that hyperstimulated CD4+ 
T cells play a major role in the pathogenesis of Hashimoto thyroiditis. T helper 1 
cells (Th1) produce interferon γ. Anti-TSHR antibodies against TSH receptor, whose 
differentiation is induced by Th1 cells, belong mainly to the IgG1 subgroup. Th1 
cells can also stimulate the production of antibodies by IL10 secretion, which in 
turn stimulates B cells. Helper T2 cells (Th2) secrete interleukin 4 (IL4) and lead to 
the stimulation and production of B cells and plasmatic cells, which produce IgG4 
antibodies against thyroid-attacking antigens (Figure 1).
Th17 cells originate from Th under the effect of various factors, i.e. TGFB, IL6, 
IL21, IL23 or STAT3. They produce interleukin 17 (IL17), involved in the promotion of 
inflammatory processes. Th17 cells show the expression of CCR6, IL23R, IL12Rβ2 and 
CD161. Their large population has been found in patients with AITD. In turn, Tregs 
make up an opposite population of lymphocytes that are mainly involved in the inhibi-
tion of immune hyperreaction; hence, their function is impaired or their number is 
decreased in various autoimmune diseases, including AITD. The analysis of the Th17/
Treg proportion in children showed a reduced number of phenotypes characteristic of 
Treg cells: CD4+IL17+/CD4+CD25+CD127− and CD4+IL17+/CD4+CD25+CD127−FoxP3+ in 
patients with Graves’ disease as compared to the control group.
Figure 1. 
Model of Grave’s diseases etiopathogenesis; APC – antigen presenting cell; M – macrophages, CD8 – cytotoxic 
cells; cells – Th1, th2.
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Inflammation is an orderly process that should result in the elimination of a 
pathogenic factor and recovery of physiological condition, thus reflecting an effec-
tive immune response. One of the major traits of inflammatory condition is its self-
limiting nature. The impaired suppresive function of lymphocytes leads ultimately 
to uncontrolled tissue injury and chronic inflammation. In the last few years, the 
maintenance of immunological tolerance has been ascribed to the subpopulation 
of B cells called B regulatory cells (Bregs). Their role has been emphasized in many 
autoimmune diseases which show both abnormal count and disturbed functionality 
of Bregs. Throughout the decades the knowledge of Bregs was based mainly on the 
research conducted on mice. The breakthrough was a study by Janeway et al., who 
in mice deprived of B cells observed a failure to recover after previous experimental 
autoimmune encephalomyelitis (EAE). Moreover, interleukin 10 (IL10) was found 
to be responsible for regulatory properties. Immature and mature B cells and 
plasmoblasts are thought to have a potential to differentiate towards Bregs produc-
ing IL10 both in mice and people. There is a strong potentiation of the function 
between Bregs and Tregs. On the other hand, Bregs inhibit differentiation of Th1 
and Th17 cells by suppressing the production of proinflammatory cytokines as well 
as proliferation of dendritic cells (Figure 2).
Apart from IL10 secretion, Bregs are characterized by the production of other 
factors, i.e. transforming growth factor β (TGFβ) and interleukin 35 (IL35) (Figure 3). 
Through the production of TGF-β, Bregs activated by lipopolysaccharide (LPS) are able 
to induce the apoptosis of effector CD4+ T cells and inactivity of CD8+ T cells. Another 
mechanism inhibiting the immune response is due to the effect of IL35 which may 
inhibit the effector function of T cells; it also induces Bregs, promotes differentiation of 
B cells to Bregs secreting not only IL35, but also IL10.
Authors still pose a question whether Bregs constitute a separate cell line, in 
which a specific factor controls the expression of the genes responsible for their 
suppresive function or appear in response to the action of specific factors that 
stimulate B cells in a suitable environment. Immature and mature B cells and plas-
moblasts and plasmatic cells may act as Bregs. Also B10 cells may differentiate into 
cells producing antibodies following termination of IL-10 production. In response 
to the inflammatory process, the level of Bregs increases and they gain the ability 
to regulate immunity. Thanks to the combination of antigen with B cell receptor 
(BCR), Bregs detect the inflammatory signal and induce regulatory effects [10–14].
Figure 2. 






The major markers of Graves’ disease include TSHR-directed autoantibod-
ies (TRAb). TSHR belongs to the family of glycoprotein hormone receptors and 
stimulates adenyl cyclase (cAMP) through G protein. The cAMP activates all the 
functions of thyroid cells, e.g. thyroglobulin synthesis, functioning of iodine pump, 
activity of thyroid peroxidase and release of hormones. Thyrotropin is a physiologi-
cal agonist for the receptor.
Three types of TSH receptor antibodies can be distinguished:
• stimulating - thyroid stimulating immunoglobulins (TSI), which imitate the 
receptor ligand and increase the level of adenyl cyclase (cAMP), thus promoting 
the production of thyroid hormones and the growth of the gland.
• blocking - thyroid blocking immunoglobulins (TBI), inhibiting the activity of 
TSH and thus leading to hypothyreosis.
• neutral, whose effect on TSH receptor has not been yet examined.
In rare cases, both TSI and TBI are present or they are changed, one into the 
other, due to treatment. In clinical studies, the level of TRAb can be assessed 
using methods based on receptor binding (the so called binding assays), used to 
detect antibodies in the blood that compete with TSH for binding to its receptor 
(TSH binding inhibitory immunoglobulins, TBII or TRAb). However, in this way 
it is impossible to differentiate between their biological, stimulating or blocking 
activity.
The newest method, the so called bioassay (biological tests), is not routinely 
applied due to high costs. It can be used to determine the level of cAMP produc-
tion after TSI binding to TSH receptor. The method is also used to monitor thyroid 
opthalmopathy and in the case of doubtful diagnosis of Graves’ disease due to 
borderline or negative TRAb values. Currently, no system is available to measure the 
activity of neutral antibodies. In our patients, TSI and TBI were determined with a 
Figure 3. 




biological test using Chinese hamster ovary cells with an embedded gene encoding 
the TSH receptor and with the luciferase system. TSI from a sample obtained from 
a patient binds to the receptor and via cAMP triggers the production of luciferase, 
thereby initiating a light reaction. The emission is measured with a luminometer. 
The measured values are compared to the reference values and in this way the pres-
ence of antibodies is confirmed or denied. The cut-off point in the analysis using 
a Thyretain TSI bioassay is the sample-to-reference ratio of more than 140% for 
the stimulating antibodies, and the degree of inhibition over 40% for the blocking 
antibodies.
Patients with hyperthyroidism and concomitant Graves’ opthalmopathy showed 
significantly higher values of TSI/TSAb before and during treatment as compared 
to hyperthyroid patients without opthalmopathy (Figure 4). Patients in the pre-
pubertal age had higher levels of TSI/TSAb than those in the pubertal age. Girls had 
significantly higher values than boys (p < 0.02) (Figures 5 and 6).
Moreover, the comparison of the proportion of positive values of TSI/TSAb 
vs. TBII in the whole group of patients with untreated Graves’ disease and 
Figure 4. 
Levels of thyroid stimulating immunoglobulins (TSAb): (A) untreated children; (B) children treated with 
Graves’ disease and with or without ophthalmopathy.
Figure 5. 






Levels of thyroid stimulating immunoglobulins (TSAb) in females and males with Graves’ disease.
Figure 7. 
Comparison of positive values of TSI/TSAb to TBII levels in all patients with Graves’ disease – untreated and 
with Graves’ disease and ophthalmopathy.
Figure 8. 
ROC curves for TSI and TBII levels in patients with Graves’ disease; (A) untreated; (B) treated.
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Graves’ disease with concomitant opthalmopathy revealed significantly higher 
values for TSAb than TBII in each group (Figure 7). The ROC curves for TSI and 
TBII in the above mentioned group of patients with Graves’ disease are presented 
in Figure 8.
Graves’ disease is also characterized by the presence of autoantibodies 
directed against various components of the thyroid, i.e. antibodies against 
thyroid peroxidase (anti-TPO), thyroglobulin (anti-TG). However, they are not 
highly specific and sensitive in the detection of this disease [15–17].
4. Clinical symptoms
Graves’ disease is a chronic disorder characterized by periods of exacerbations 
and remissions, with a differentiated clinical picture, slightly different in chil-
dren as compared to adults. In the pediatric population, the CNS shows higher 
sensitivity to the excess of thyroid hormones and lower to the circulatory system. 
On the physical examination, the patient presents with restless behaviour and 
body mass deficiency despite good appetite. The child’s skin becomes smooth, 
warm and moist, and the goiter is the most constant symptom. The thyroid goiter 
is usually evenly enlarged, with parenchymal density, smooth and painless. On 
palpation, throbbing and tremour of the gland can be felt, caused by enhanced 
blood flow, well heard (when auscultated above the thyroid) as a vascular 
murmur, mainly in the upper poles of the gland. The heart action is markedly 
accelerated and does not slow down at rest. In hyperthyroidism observed in the 
prepubertal group the growth rate and bone age advancement are accelerated due 
to increased release of growth hormone. The excess of thyroid hormones in early 
childhood is manifested by physical overreaction and concentration disorders. 
This effect is associated with the particular sensitivity of the CNS to the thyroid 
hormones, which affect α- and β-adrenergic postsynaptic receptors and increase 
serotonin release. In the prepubertal Graves’ group neuropsychiatric symptoms 
have been observed including hyperirritability, locomotor anxiety, sleep and con-
centration disorders, which are manifested as worse academic performance and 
emotional lability. Ophthalmopathy in children with Graves’ disease is generally 
mild in nature and ocular lesions subside along with normalization of thyroid 
hormone secretion. Infiltrative-hydropic exophthalmos is rare. Pretibial edema 
in the pediatric group has a location similar to that in adults but is different in 
nature: it is soft and not well separated. Table 1 presents the effect of hyperthy-
roidism on the respective systems.
Graves’ disease occurs in children with other autoimmune diseases, such 
as type 1 diabetes, Addison’s disease, albinism, systemic lupus erythematosus, 
miastenia gravis, juvenile idiopathic arthritis, autoimmune thrombocytopenia, 
Addison-Biermer anemia. The risk of the disease is increased in children with 
trisomy 21, Turner syndrome and DiGeorge syndrome. In diabetic children meta-
bolic balance is difficult to achieve. The course of the disease in these patients 
with concomitant hyperthyroidism is labile and it is difficult to compensate for 
glycemia. Demand for insulin increases, mainly as a result of developing insulin 
resistance and fast tissue insulin metabolism. At the same time intestinal glucose 
absorption is increased, gluconeogenesis is enhanced and glycogen synthesis is 
decreased. Moreover, in the states of thyrotoxicosis the secretion of growth hor-
mone, which is also responsible for glycemia increase is elevated. In consequence, 





5.1 Medical history and clinical examination
A detailed medical history and thorough clinical examination are indispensable 
for proper diagnosis. Clinical diagnosis of primary hyperthyroidism is confirmed 
by elevated levels of circulating thyroid hormones and TSH suppression to the 
values close to zero. In rare cases of hyperthyroidism, such as thyreotropinoma, 
ectopic TSH secretion and pituitary resistance to thyroid hormones, serum TSH 
level is usually elevated or inadequately normal, whereas the levels of thyroid 
hormones (fT4 i/lub fT3) are increased. With autoimmunization in Graves’ disease, 
the level of anti-TSHR antibodies is elevated. High titer of these antibodies allows 
for the exclusion of the toxic phase of Hashimoto thyroidits (hashitoxicosis) and 
subacute thyroiditis. Other antithyroid antibodies (a-TPO and a-ATG) are of minor 
importance. Very seldom, the co-occurrence of Graves’ disease and hashitoxicosis 
determines a positive titer of anti-TSHR antibodies.
5.2 Imaging investigations
Imaging investigations- thyroid ultrasound - is a subsequent stage in the 
diagnosis of hyperthyroidism; however, it is not indispensable for the diagnosis 
Organs Symptoms
Nervous system Nervousness, irritability, emotional lability, sleep disturbance, headaches, learning 
difficulties, trembling of fingers, toes, tongue- fine tremor; motor incoherence, muscle 
weakness, excessive fatigue, especially of proximal muscles of limbs; reduction of 
tendon reflexes’ duration;
Skin Smooth, soft, satin skin; increased sweating and moistness; intensified warmth of the 
skin; vivid dermographism; delicate and breakable hair;
Eyes Von Graefe’s, Kocher’s, Stellwag’s, Popow’s, Dalrynple’s, Joffroy’s signs- mild symptoms 
caused by stimulation of the sympathetic nevous system; Moebius’ sign- lack of 
convergence; exophthalmos- bulging of the eye anteriorly out of the orbit;
Bones Acceleration of growth rate and maturation of bone age in children; final height lower 
than expected due to early overgrowth of epiphyseal cartilages; intensive decay; limbs’ 
pain; osteoporosis- typical for adults;
Circulatory 
system
Constant tachycardia; increase of systolic BP, decrease of diastolic BP (high amplitude 
of blood pressure); heart arythmia- premature atrial contractions, atrial fibrillation 
(especially in newborns); systolic murmur caused by hyperkinetic circulation; in ECG: 
increase of QRS amplitude; disturbance of repolarization phase; echocardiography: 
signs of hyperkinetic circulation;
Digestive system Increased appetite combined with weight loss; accelerated intestinal passage and 
increased number of defecations; fatty diarrheas caused by inadequate secretion 
of pancreatic enzymes due to accelerated gastric emptying and increased intestinal 
peristalsis; absorption disorders;
Urinary tract Increased thirst and polyuria due to increased index of glomerular filtration; 
hypercalcaemia, as the most frequent electrolyte disturbance in hyperthyroidism, 




Menstrual disorders; secondary lack of menstruation; decreased libido;
Table 1. 
Impact of hyperthyroidism on different systems.
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of Graves’ disease. In autoimmune hyperactivity, the thyroid is usually enlarged, 
with reduced echogenicity and markedly increased blood flow in color Doppler 
ultrasound (CDUS) and in power Doppler examination, with moderately 
increased flow in non-autoimmune hyperactivity caused by active mutation in 
TSH-R (Figures 9 and 10). Currently, due to high access to anti-TSHR antibody 
titer assays, gland scintigraphy with I123 or Tc99 is seldom performed. It used to 
be widely applied to differentiate between Graves’ disease, thyrotoxic phase 
of chronic lymphocytic thyroiditis, subacute thyroiditis and a hormonally 
active nodule.
5.3 Other examinations
If nodular lesions coexist, fine-needle aspiration biopsy (FNAB) of the thyroid 
should be performed. Elastography remains a complementary method to differenti-
ate nodules [18].
Figure 9. 
Ultrasound image of hyperthyroidism in the course of active mutation in TSH receptor: (a) thyroid gland 
slightly enlarged bilaterally, inhomogeneous, hypoechogenic; (b) moderately increased vascular flow in Doppler 
ultrasonography.
Figure 10. 
Ultrasound image of hyperthyroidism in the course of Graves’ disease: (a) thyroid gland enlarged 





6. Treatment of hyperthyroidism
In most common type of hyperthyroidism in children with Graves’ disease 
causal treatment is unknown. The management involves pharmacotherapy (thy-
rostatics, β-adrenolitics), although sometimes radical radioiodine I131 therapy or 
surgical treatment is necessary. Some world literature reports indicate the applica-
tion of immunotherapy in Graves ophtalmopathy in adults using rituximab (mono-
clonal anti-CD20 antibodies) to delete B cells. Thorough knowledge of the structure 
of human antibodies stimulating (M22) and blocking (Ki-70) TSHR has given great 
hope for their immunotherapeutic use in humans, including possible administra-
tion of blocking antibodies (TBI) to treat severe thyroid ophthalmopathy in the 
course of Graves’ disease. In children, conservative treatment with thyrostatics is 
most frequently used.
In clinical practice, two basic methods are used:
• the so called combined method (“block and replace” regimen), consisting in 
the inhibition of the production of thyroid hormones with a thyrostatic and 
administration of levothyroxin at a replacement dose (less recommended 
currently).
• adaptive method (titration regimen), based on monotherapy with a thyro-
static; smaller doses of the drug are used depending on the levels of thyroid 
hormones.
6.1 Thyrostatics
It is assumed that treatment with thyrostatics until eutyreosis is obtained usu-
ally lasts a few weeks (2–6 weeks), and complete treatment with gradually decreas-
ing doses should be conducted for 24–36 months (Figure 11A). When Graves’ 
disease occurs in the prepubertal period the time of therapy prolons to 3–6 years 
(Figure 11B). In children thiamazoles are administered, namely imidazole, thiam-
azole (administered in one or two doses; 0.3–0.6 mg/kg/24 h, max. 30 mg/24 h), 
carbimazole (two or three doses daily; 0.4–0.8 mg/kg/24 h.
Propylothiouracyl, which 12–15 years ago used to be the most commonly 
administered medicine in the USA in the therapy of Graves’ disease, currently is 
not recommended and even contraindicated due to increased risk of severe liver 
damage. FDA reports have indicated that 1:2000 children may develop severe liver 
failure that will require transplantation as a consequence of propylothiouracyl 
administration. In 1:200 children reversible propylothiouracyl-dependent liver 
damage will occur. The only way to avoid liver injury is to withdraw this drug, 
limiting its use only to patients who are allergic to thiamazole and who have to 
be prepared to surgery or in children sensitive to thiamazole whose parents do 
not give their consent to radical treatment, as well as in the first trimester of 
pregnancy.
A -adrenolitic drug (athenolol 1–2 mg/kg in one dose or propranolol  
1–2 mg/kg in 2–3 doses) is also administered for the first 2–4 weeks until euthy-
reosis is achieved to monitor hyperactivation of the cardiovascular system. 
Serum levels of fT3 and fT4 get normalized after 2–6 weeks, whereas TSH can be 
inhibited for a few months (3–6 on average). Therefore, in the initial phase of the 
treatment peripheral hormones should be monitored. Thyroid hormones usu-
ally need to be measured after 2 weeks, one month and then every month until 
TSH normalization. When f T3 and f T4 become normal the thyrostatic dose is 
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decreased by 30–50%, and then after the subsequent 3–6 weeks depending on the 
level of the hormones to the maintenance dose of 5–15/24 h. The persistence of 
antireceptor antibodies and difficulty in obtaining euthyrosis indicate high risk of 
relapse. Thus, remission is strictly related to the titer of TSI antibodies. When the 
titer is high, the chance of remission is 15%, and with a low titer approximately 
50% of patients enter remission. Therefore, already at the start of the therapy, 
determination of TSI antibodies may help predict which patients are likely to 
achieve long-term remission of the disease.
Figure 11. 
(A) Schemes of Graves’ disease treatment strategies: A option (Figure 11A) and B option (Figure 11B).  
(B) Schemes of Graves’ disease treatment strategies: A option (Figure 11A) and B option (Figure 11b). Based 




The incidence of side-effects depends on the thyrostatic dose. All antithyroid 
drugs may cause goiter. Other undesirable effects include skin disorders, such as 
pruritus, urticarial or erythematosus exanthema, dyspepsia, arthralgia or transitory 
granulocytopenia (<1500 granulocytes/mm3).
Agranulocytosis is rare (approximately 0.2% of cases). It should be remem-
bered that as hyperthyreosis may lead to moderately increased neutropenia, 
complete blood cell count should be done prior to treatment and in any case of 
fever or strep throat. When the level of neutrophils is <1000/mm3, the treatment 
should be discontinued or the dose decreased; at <500/mm3 – further treatment is 
contraindicated.
In turn, the level of transaminases should be assessed prior to treatment imple-
mentation and possibly when a thyrostatic is introduced. Regular control of liver 
function is not justified. If symptoms of jaundice, gastrointestinal dysfunction or 
pruritis appear, measurements should include liver enzymes (ASPAT, ALT), total 
and bound bilirubin and ALP. Cholestatic jaundice, hepatitis or lupus-like syn-
drome are rare.
Other side-effects after propylothiouracyl administration include hepato-, 
neuro- and myelotoxic effects (with thrombocytopenia and agranulocytosis <250 
granulocytes/mm3) and vasculitis with the presence of ANCA antibodies. Thus, in 
the light of the current knowledge, children should not be treated with propylothio-
uracyl, and the recommended therapy should be based on thiamazole, radioactive 
iodine or surgery [19–22].
6.2 Radioiodine therapy
Radioiodine therapy is usually restricted to patients who are resistant to phar-
macological treatment and who do not enter remission, or when they develop toxic 
reaction to a drug or have not complied with doctor’s recommendations. The aim of 
the therapy is total destruction of the thyroid parenchyma by applying an ablative 
dose and in consequence obtaining permanent hypothyroidism. The advantages 
include easy application, lack of long-term side-effects and high efficacy of the first 
dose (approximately 95%). In the relapse of hyperthyroidism the subsequent dose 
of radioiodine can be administered 6 months after the first dose.
Young age (>5 years) is not a contraindication for this therapy, although much 
caution is required in children younger than 10. The risk of thyroid cancer in 
children exposed to I131 is the highest in those younger than 5 years due to increased 
vulnerability of the thyroid tissue to proliferative effects of ionizing radiation and 
gradually decreases in older age groups. Thus, children receive higher doses of 
radioiodine, i.e. a constant dose of 15 mCi, or doses dependent on the gland mass 
and its iodine uptake potential (150–200 μCi/g of thyroid tissue; 5.5–7.4 Mq/g; 12 
000–16 000 cGy/g), so that to minimize the risk of secondary neoplasms. The 
radioiodine therapy should be followed by thyroxin substitution to manage hypo-
thyroidim and avoid TSH increase. There is also no evidence that in the offspring of 
patients treated with I131 due to hyperthyreosis or thyroid cancer the risk of genetic 
defects is elevated (it is comparable to the risk noted in the general population).
Iodine (I131) is usually administered after a break of 5–7 days in the application of 
the thyrostatic. Some suggest that antithyroid therapy should not be disrupted and 
the I131 dose needs to be increased by 20% to avoid the risk of an overactive thyroid 
storm. Otherwise, the use of -adrenolites and antiinflammatory non-steroids should 
be recommended to attenuate the symptoms of postradiation thyroiditis. Moreover, 
less common are nausea, pruritis of the neck skin, hypoparathyroidism or exacerba-
tion of Graves ophthalmopathy. In this latter case, even though enhanced opthal-
mopathy in children is not frequent, protective treatment with glycocorticosteroids 
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for 6–8 weeks should be considered (some recommend 3 months after radioiodine 
administration). Prolonged steroid therapy may have an effect on growth cartilage 
and body mass, and shows immunosuppresive action. Contraindications to radioio-
dine therapy are at the same time indications for surgery: large goiter >80 g, pressure 
symptoms, severe thyrotoxicosis with accompanying neurological symptoms, lack of 
iodine uptake of the thyroid, suspicion of a neopastic lesion, severe ophthalmopathy, 
age < 5 years, pregnancy and lactation, and also lack of consent to I131 treatment.
6.3 Surgical treatment
Surgical treatment of Graves’ disease is the oldest therapeutic method and total 
thyroidectomy which prevents relapse of hyperthyroidism is currently recom-
mended. However, it is burdened with the risk of retrograde laryngeal nerve injury, 
hypoparathyroidism and more seldom hypothyroidism relapse (referring to 1–5% 
of children after total thyroidectomy vs. approximately 10–20% after partial or 
subtotal thyroidectomy). Sporadically, infection or keloid is observed at the site of 
the postoperative scar. The risk of complications depends to a large extent on the 
skills and experience of a surgeon. Importantly, prior to surgery a patient has to be 
treated with a thyrostatic drug and be in euthyreosis, receive iodide preparations 
(e.g. Lugol’s solution or potassium iodide) 7–10 days before, 3–7 drops, each dose 
twice daily to reduce thyroid gland vascularity.
6.4 Excision of thyroid tissue
In rare cases of hyperthyroidism in children that is caused by the presence of 
autonomic tissue, radical treatment with thyroid removal or administration of abla-
tion doses of radioiodine is recommended. In the state of thyroid hormone poison-
ing, the hormones need to be withdrawn and a -adrenolitic drug, e.g. propranolol, 
should be administered.
The therapy should be individually tailored and discussed both with the patient 
and the family [23–26].
7. Conclusions
• The diagnosis of Graves’ disease in children is based mainly on the determina-
tion of TSH suppresion and the presence of anti-TSHR antibodies.
• Thyroid ultrasound is not indispensable for the diagnosis; however, it allows 
for the assessment of the gland size and homogeneity.
• Scintigraphy is not required to diagnose Graves’ disease.
• The measurement of T4 and T3 is not obligatory in the diagnosis of Graves’ 
disease in children, but it is useful for treatment monitoring and to assess the 
prognosis of the disease relapse.
• Lack of anti-TSHR antibodies may suggest genetically inherited 
hyperthyroidism.
• The first-line treatment of Graves’ disease in children involves pharma-
cotherapy with imidazole, carbimazole, thiamazole at the initial dose of 
0.4–0.8 mg/kg/24 h (0.3–0.6 mg/kg/24 h for thiamazole) depending on the 




• Propylothiouracyl is contraindicated for children.
• Depending on patient’s age, disease severity and the presence of anti-TSHR 
antibodies the initial therapy should last 3–6 years.
• Prior to the treatment implementation, peripheral blood cell count measure-
ment should be performed to assess the grade of neutropenia caused by 
hyperthyroidism. Regular determination of blood count during check-ups is 
not necessary.
• Blood count should be performed if the patient is feverish or has strep 
throat. Neutrophil count <1000/mm3 is an indication for treatment discon-
tinuation or dose reduction; <500/mm3 - further treatment is absolutely 
contraindicated!
• The level of transaminases should be determined prior to treatment. Regular 
control of liver function is not justified.
• When jaundice, gastrointestinal tract dysfunction or pruritis appear, liver 
enzymes (ASPAT, ALAT), total and bound bilirubin and ALP should be 
determined..
• Patients and their parents should be informed about possible side-effects of 
thyrostatics.
• Patients and their families should be informed about prognosis (50% of 
patients obtain remission after a few years of treatment) and possibilities of 
radical treatment.
• Female patients with Graves’ disease (both in the course of remission and after 
radical treatment) require endocrinology care prior to and during planned 
pregnancy.
• Indications for radical treatment include contraindications to pharmacology, 
poor results of pharmacotherapy, repeated prolongation of therapy, parents’ 
and child’s request.
• Thyroidectomy is a radical method applied in children before the age of 5 years 
or in the case of large goiter, nodular goiter or goiter pressing the organs.
• The experience of a surgeon performing thyroidectomy in children is the major 
factor responsible for postoperative complications.
• Radioiodine therapy is recommended after the age of 5 years if the goiter is not 
too large (more frequently in puberty).
• Education of patients and parents is important to ensure the best possible 
response to treatment.
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